Vulnerabilities of PTEN-p53-deficient prostate cancers to compound PARP/PI3K inhibition

Prostate cancer (CaP) is the most prevalent cancer in males and treatment options are limited for advanced forms of the disease. Loss of the PTEN and p53 tumor suppressor genes is commonly observed in CaP, while their compound loss is often observed in advanced CaP. Here we show, that PARP inhibitio...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: González-Billalabeitia, Enrique, Seitzer, Nina, Song, Su Jung, Song, Min Sup, Patnaik, Akash, Liu, Xue-Song, Epping, Mirjam T., Papa, Antonella, Hobbs, Robin M., Chen, Ming, Lunardi, Andrea, Ng, Christopher, Webster, Kaitlyn A., Signoretti, Sabina, Loda, Massimo, Asara, John M., Nardella, Caterina, Clohessy, John G., Cantley, Lewis C., Pandolfi, Pier Paolo
פורמט: Artigo
שפה:Inglês
יצא לאור: 2014
נושאים:
Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC4125493/
https://ncbi.nlm.nih.gov/pubmed/24866151
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-13-0230
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים